Physical Function During ARSI Treatment

Inclusion Criteria:

Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
Subjects is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.
Age ≥ 18 years at the time of consent.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Diagnosis of metastatic disease from prostate cancer, or recurrent disease following definitive local therapy of prostate cancer, as assessed by their clinician
Initiation of an ARSI (e.g., abiraterone, enzalutamide, apalutamide, or darolutamide) for mPC with concurrent androgen deprivation therapy (ADT).
Availability to begin baseline testing within 8 weeks of ARSI treatment initiation.
Physician clearance to perform physical assessments.
Ability to speak and read English.

Exclusion Criteria:

Prior ARSI treatment
Current chemotherapy
History of bone fractures or musculoskeletal injuries
Neurological conditions that affect balance and/or muscle strength
Intention to leave the region prior to completion of study
Dementia, altered mental status or any psychiatric condition prohibiting the understanding or rendering of informed consent